Literature DB >> 34716024

Increasing global accessibility to high-level treatments for cervical cancers.

C Chargari1, M Arbyn2, A Leary3, N R Abu-Rustum4, P Basu5, F Bray6, S Chopra7, R Nout8, K Tanderup9, A N Viswanathan10, C Zacharopoulou11, J C Soria12, E Deutsch13, S Gouy14, P Morice15.   

Abstract

Human papillomaviruses (HPV)-related gynecological cancers are a major health care issue, and a leading cause of cancer death in low- and middle-income countries (LMIC). In 2020, the World Health Organization launched a program aimed at cervical cancer elimination, by screening and vaccination strategies. Offering the best possible care to women diagnosed with invasive cancer is a complementary objective. Treatment of cervical cancer as per modern standards is complex and multimodal, mainly relying on surgery, external-beam radiotherapy (+/-chemotherapy) and brachytherapy. In parallel with the pivotal role of multidisciplinary discussion, international societies provide guidance to define the most effective and least toxic anti-cancer strategy, homogenize treatment protocols and provide benchmark quality indicators as a basis for accreditation processes. The challenge is to offer the appropriate diagnostic workup and treatment upfront and to avoid non- evidence-based treatment that consumes resources, impairs quality of life (QoL), and compromises oncological outcome. Various strategies may be applied for improving treatment quality: development of surgical mentorship, companion-training programs and international cooperation. The lack of radiotherapy/brachytherapy facilities is a major concern in LMIC. Reinforcing international support in terms of education, training, research and development and technical cooperation with national projects is required to increase access to minimum requirements but also introduce modern techniques, upgrade radiotherapy/brachytherapy services, and expand access to modern systemic treatments. In countries with robust economies, compliance to standards should also be increased. Integrative cancer care and multidisciplinary approaches are needed to tackle the dual challenge of increasing cure rates while minimizing QoL impairment. Appropriate dimensioning of the resources to avoid harmful treatment delays and access to expert referral centers is also a priority.
Copyright © 2021. Published by Elsevier Inc.

Entities:  

Keywords:  Brachytherapy; Cervical cancer; Cervix; Human papillomaviruses (HPV); Radiotherapy; Surgery

Mesh:

Year:  2021        PMID: 34716024      PMCID: PMC9496636          DOI: 10.1016/j.ygyno.2021.10.073

Source DB:  PubMed          Journal:  Gynecol Oncol        ISSN: 0090-8258            Impact factor:   5.304


  84 in total

1.  Neoadjuvant Chemotherapy Followed by Radical Surgery Versus Concomitant Chemotherapy and Radiotherapy in Patients With Stage IB2, IIA, or IIB Squamous Cervical Cancer: A Randomized Controlled Trial.

Authors:  Sudeep Gupta; Amita Maheshwari; Pallavi Parab; Umesh Mahantshetty; Rohini Hawaldar; Supriya Sastri Chopra; Rajendra Kerkar; Reena Engineer; Hemant Tongaonkar; Jaya Ghosh; Seema Gulia; Neha Kumar; T Surappa Shylasree; Renuka Gawade; Yogesh Kembhavi; Madhuri Gaikar; Santosh Menon; Meenakshi Thakur; Shyam Shrivastava; Rajendra Badwe
Journal:  J Clin Oncol       Date:  2018-02-12       Impact factor: 44.544

2.  Trends in cervical cancer incidence and mortality in the Baltic countries, Bulgaria and Romania.

Authors:  Marc Arbyn; Jerome Antoine; Margit Mägi; Giedre Smailyte; Aivars Stengrevics; Ofelia Suteu; Zdravka Valerianova; Freddie Bray; Elisabete Weiderpass
Journal:  Int J Cancer       Date:  2011-04-15       Impact factor: 7.396

3.  Safety and Efficacy of Pembrolizumab in Advanced, Programmed Death Ligand 1-Positive Cervical Cancer: Results From the Phase Ib KEYNOTE-028 Trial.

Authors:  Jean-Sebastien Frenel; Christophe Le Tourneau; Bert O'Neil; Patrick A Ott; Sarina A Piha-Paul; Carlos Gomez-Roca; Emilie M J van Brummelen; Hope S Rugo; Shari Thomas; Sanatan Saraf; Reshma Rangwala; Andrea Varga
Journal:  J Clin Oncol       Date:  2017-11-02       Impact factor: 44.544

4.  Evaluation of planning aims and dose prescription in image-guided adaptive brachytherapy and radiochemotherapy for cervical cancer: Vienna clinical experience in 225 patients from 1998 to 2008.

Authors:  Katarina Majercakova; Richard Pötter; Christian Kirisits; Susovan Banerjee; Alina E Sturdza; Petra Georg; Nicole Nesvacil; Maximilian P Schmid
Journal:  Acta Oncol       Date:  2015-07-22       Impact factor: 4.089

5.  Trends of cervical cancer mortality in the member states of the European Union.

Authors:  Marc Arbyn; Amidu O Raifu; Elisabete Weiderpass; Freddie Bray; Ahti Anttila
Journal:  Eur J Cancer       Date:  2009-08-18       Impact factor: 9.162

Review 6.  Reducing uncertainties about the effects of chemoradiotherapy for cervical cancer: a systematic review and meta-analysis of individual patient data from 18 randomized trials.

Authors: 
Journal:  J Clin Oncol       Date:  2008-11-10       Impact factor: 44.544

7.  National cancer control plans: a global analysis.

Authors:  Yannick Romero; Dario Trapani; Sonali Johnson; Zuzanna Tittenbrun; Leslie Given; Karin Hohman; Lisa Stevens; Julie S Torode; Mathieu Boniol; André M Ilbawi
Journal:  Lancet Oncol       Date:  2018-09-26       Impact factor: 41.316

8.  Radiation therapy for gynecologic malignancies during the COVID-19 pandemic: International expert consensus recommendations.

Authors:  Christen R Elledge; Sushil Beriwal; Cyrus Chargari; Supriya Chopra; Beth A Erickson; David K Gaffney; Anuja Jhingran; Ann H Klopp; William Small; Catheryn M Yashar; Akila N Viswanathan
Journal:  Gynecol Oncol       Date:  2020-06-15       Impact factor: 5.482

9.  Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study.

Authors:  Tim Palmer; Lynn Wallace; Kevin G Pollock; Kate Cuschieri; Chris Robertson; Kim Kavanagh; Margaret Cruickshank
Journal:  BMJ       Date:  2019-04-03

10.  Estimates of the global burden of cervical cancer associated with HIV.

Authors:  Dominik Stelzle; Luana F Tanaka; Kuan Ken Lee; Ahmadaye Ibrahim Khalil; Iacopo Baussano; Anoop S V Shah; David A McAllister; Sami L Gottlieb; Stefanie J Klug; Andrea S Winkler; Freddie Bray; Rachel Baggaley; Gary M Clifford; Nathalie Broutet; Shona Dalal
Journal:  Lancet Glob Health       Date:  2020-11-16       Impact factor: 26.763

View more
  4 in total

Review 1.  Economic Perspective of Cancer Care and Its Consequences for Vulnerable Groups.

Authors:  Joerg Haier; Juergen Schaefers
Journal:  Cancers (Basel)       Date:  2022-06-28       Impact factor: 6.575

Review 2.  Current Standards in the Management of Early and Locally Advanced Cervical Cancer: Update on the Benefit of Neoadjuvant/Adjuvant Strategies.

Authors:  Yuedan Zhou; Elie Rassy; Alexandre Coutte; Samir Achkar; Sophie Espenel; Catherine Genestie; Patricia Pautier; Philippe Morice; Sébastien Gouy; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2022-05-16       Impact factor: 6.575

3.  Providing Patients with Locally Advanced Cervical Cancer Access to Brachytherapy: Experience from a Referral Network for Women Treated in Overseas France.

Authors:  Rita Bentahila; Elie Rassy; Samir Achkar; Florence Sacino; Stefanos Bougas; Alexis Vallard; Vincent Vinh-Hung; Johan Encaoua; Pierre Gustin; Sylvie Mengue; Patricia Pautier; Philippe Morice; Sébastien Gouy; Sophie Espenel; Eric Deutsch; Cyrus Chargari
Journal:  Cancers (Basel)       Date:  2022-06-14       Impact factor: 6.575

4.  RGS1 and related genes as potential targets for immunotherapy in cervical cancer: computational biology and experimental validation.

Authors:  Siyang Zhang; Han Wang; Jiao Liu; Tao Tao; Zhi Zeng; Min Wang
Journal:  J Transl Med       Date:  2022-07-25       Impact factor: 8.440

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.